Corrigendum to "European-evidence-based consensus on the management of ulcerative colitis: Current management" [J Crohns & Colitis 2 (2008) 24-62] (DOI:10.1016/j.crohns.2007.11.002);European evidence-based Consensus on the management of ulcerative colitis: Current management

Journal of Crohn's and Colitis

Volumn 2, Issue 1, 2008, Pages 24-62

  Travis, S P L ^a   Stange, E F ^a   Lemann M ^a   Oresland T ^a   Bemelman, W A ^a   Chowers, Y ^a   Colombel, J F ^a   D'Haens, G ^a   Ghosh, S ^a   Marteau, P ^a   Kruis, W ^a   Mortensen, N J McC ^a   Penninckx, F ^a   Gassull, M ^a  

^a NONE

Author keywords

Acute severe colitis; Azathioprine; Ileal pouch anal anastomosis; Infliximab; Mesalazine; Ulcerative colitis

Indexed keywords

12 SULFODEHYDROABIETIC ACID; ACETARSOL; ADALIMUMAB; AMINOSALICYLIC ACID; AMOXICILLIN; AZATHIOPRINE; BECLOMETASONE DIPROPIONATE; BETAMETHASONE; BISMUTH CARBOMER; BISMUTH DERIVATIVE; BUDESONIDE; CORTICOSTEROID; CYCLOSPORIN A; HYDROCORTISONE; INFLIXIMAB; LIDOCAINE; MESALAZINE; MESREN; METHOTREXATE; METHYLPREDNISOLONE; METRONIDAZOLE; NICOTINE; NICOTINE TARTRATE; PLACEBO; PREDNISOLONE; REBAMIPIDE; ROPIVACAINE; SALAZOSULFAPYRIDINE; TACROLIMUS; TETRACYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APPENDECTOMY; BASAL CELL CARCINOMA; BONE MARROW SUPPRESSION; CLINICAL FEATURE; CLINICAL TRIAL; COLON RESECTION; COLONOSCOPY; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DISEASE ACTIVITY; DISEASE COURSE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; FOLLOW UP; GASTROINTESTINAL BIOPSY; GASTROINTESTINAL SYMPTOM; HEADACHE; HISTOPLASMOSIS; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; ILEOSTOMY; INTERSTITIAL NEPHRITIS; INTESTINE FUNCTION; KIDNEY FAILURE; LAPAROSCOPY; MONOTHERAPY; NAUSEA; NEPHROTIC SYNDROME; NEUROPATHY; PANCREATITIS; PARESTHESIA; PERIOPERATIVE PERIOD; PNEUMONIA; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROCTOCOLECTOMY; RANDOMIZED CONTROLLED TRIAL; RASH; RELAPSE; REVIEW; RISK FACTOR; SINGLE DRUG DOSE; STEROID THERAPY; THROMBOCYTOPENIA; TOXIC MEGACOLON; TREATMENT OUTCOME; TREMOR; TUBERCULOSIS; ULCERATIVE COLITIS;

EID: 38749095183     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2008.03.001     Document Type: Erratum

References (372)

1. Silverberg M.S., Satsangi J., Ahmad T., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 19 suppl A (2005) 5A-36A
2. D'Haens G., Sandborn W.J., Feagan B.G., et al. Clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 132 (2007) 763-786
3. Truelove S.C., and Witts L.J. Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J ii (1955) 1041-1048
4. Turner D., Walsh C., Steinhart A.H., and Griffiths A.M. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 5 (2007) 103-110
5. Travis S.P.L., Farrant J.M., Ricketts C., et al. Predicting outcome in severe ulcerative colitis. Gut 38 (1996) 905-910
6. Rice-Oxley J.M., and Truelove S.C. Ulcerative colitis: course and prognosis. Lancet i (1950) 663-666
7. Kornbluth A., and Sachar D.B. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology Practice and Parameters committee. Am J Gastroenterol 99 (2004) 1371-1385
8. Hanauer S.B., Sandborn W.J., Kornbluth A., et al. Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol 100 (2005) 2478-2485
9. Su C., Lewis J.D., Goldberg B., Brensinger C., and Lichtenstein G.R. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology 132 (2007) 516-526
10. Van Bodegraven A.A., Boer R.O., Lourens J., Tuynman H.A.R.E., and Sindram J.W. Distribution of mesalazine enemas in active and quiescent ulcerative colitis. Aliment Pharmacol Ther 10 (1996) 327-332
11. Marshall J.K., and Irvine E.J. Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Aliment Pharmacol Ther 9 (1995) 293-300
12. Marshall J.K., and Irvine E.J. Rectal corticosteroids vs alternative treatment in ulcerative colitis: a meta-analysis. Gut 40 (1997) 775-781
13. Gionchetti P., Rissole F., Ventura A., et al. Comparison of mesalazine suppositories in proctitis and distal proctosigmoiditis. Aliment Pharmacol Ther 11 (1997) 1053-1057
14. Regueiro M., Loftus Jr. E.V., Steinhart A.H., and Cohen R.D. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis 12 (2006) 979-994
15. Gionchetti P., Rizzello F., Venturi A., et al. Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Dis Colon Rectum 41 (1998) 93-97
16. Safdi M., DeMicco M., Sninsky C., et al. A double-blind comparison of oral vs rectal mesalamine vs combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 92 (1997) 1867-1871
17. Mulder C.J.J., Fockens P., Meijer J.W.R., et al. Beclomethasone dipropionate (3mg) vs 5-aminosalicylic acid (2g) vs the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. Eur J Gastroenterol Hepatol 8 (1996) 549-553
18. Marteau P., Probert C.S., Lindgren S., et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 54 (2005) 960-965
19. Frieri G., Giacomelli R., Pimpo M., et al. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. Gut 47 (2000) 410-416
20. Frieri G., Mariateresa P., Brigida G., et al. Long-term oral plus topical mesalazine in frequently relapsing ulcerative colitis. Dig Liver Dis 37 (2005) 92-96
21. Sutherland L., and MacDonald J.K. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2 (2006) CD000543
22. Bebb J.R., and Scott B.B. How effective are the usual treatments for ulcerative colitis?. Aliment Pharmacol Ther 20 (2004) 143-149
23. Lichtenstein G., Kamm M., Boddu P., et al. Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 5 (2007) 95-102
24. Kamm M.A., Sandborn W.J., Gassull M., et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 132 (2007) 66-75
25. Sandborn W.J., Kamm M.A., Lichtenstein G.R., et al. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Aliment Pharmacol Ther 26 (2007) 205-215
26. Campieri M., Adamo S., Valpiani D., et al. Oral beclometasone dipropionate in the treatment of extensive and left-sided active ulcerative colitis: a multicentre randomised study. Aliment Pharmacol Ther 17 (2003) 1471-1480
27. Kane S.V., and Bjorkman D.J. The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review. Rev Gastroenterol Disord 3 (2003) 210-218
28. Truelove S.C., Watkinson G., and Draper G. Comparison of corticosteroid and SASP therapy in ulcerative colitis. Br Med J 2 (1962) 1708-1711
29. Lennard-Jones J.E., Longmore A.J., Newell A.C., Wilson C.W.E., and Avery Jones F. An assessment of prednisone, Salazopyrin and topical hydrocortisone hemisuccinate used as outpatient treatment for ulcerative colitis. Gut 1 (1960) 217-222
30. Baron J.H., Connell A.M., Kanaghinis T.G., et al. Outpatient treatment of ulcerative colitis: comparison between three doses of oral prednisone. Br Med J 2 (1962) 441-443
31. Lofberg R., Danielsson A., Suhr O., et al. Oral budesonide vs prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology 110 (1996) 1713-1718
32. Cameron E.A., Binnie J.A., Balan K., et al. Oral prednisolone metasulphobenzoate in the treatment of active ulcerative colitis. Scand J Gastroenterol 38 (2003) 535-537
33. Edwards F.C., and Truelove S.C. The course and prognosis of ulcerative colitis. Gut 4 (1963) 299-315
34. Hardy T.L., and Bulmer E. Ulcerative colitis: survey of 95 cases. Br Med J ii (1933) 812-815
35. Jakobovits S., and Travis S.P.L. The management of acute severe ulcerative colitis. Br Med Bull 75-76 (2006) 131-144
36. Truelove S.C., and Jewell D.P. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet i (1974) 1067-1070
37. Rosenberg W., Ireland A., and Jewell D.P. High-dose methylprednisolone in the treatment of active ulcerative colitis. J Clin Gastroenterol 12 (1990) 40-41
38. Bossa F., Fiorella S., Caruso N., et al. Continuous infusion vs bolus administration of steroids in severe attacks of ulcerative colitis: a randomized, double-blind trial. Am J Gastroenterol 102 (2007) 601-608
39. Gan S.I., and Beck P.L. A new look at toxic megacolon: an update and review of incidence, etiology, pathogenesis, and management. Am J Gastroenterol 98 (2003) 2363-2371
40. Irving P.M., Pasi K.J., and Rampton D.S. Thrombosis and inflammatory bowel disease. Clin Gastroenterol Hepatol 3 (2005) 617-628
41. Gonzalez-Huix F., Fernandez-Banares F., Esteve-Comas M., et al. Enteral vs parenteral nutrition as adjunct therapy in acute ulcerative colitis. Am J Gastroenterol 88 (1993) 227-232
42. McIntyre P.B., Powell-Tuck J., Wood S.R., et al. Controlled trial of bowel rest in the treatment of severe acute colitis. Gut 27 (1986) 481-485
43. Dickinson R.J., O'Connor H.J., Pinder I., et al. Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut 26 (1985) 1380-1384
44. Chapman R.W., Selby W.S., and Jewell D.P. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut 27 (1986) 1210-1212
45. Burke D.A., Axon A.T., Clayden S.A., et al. The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Ther 4 (1990) 123-129
46. Mantzaris G.J., Hatzis A., Kontogiannis P., and Triadaphyllou G. Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol 89 (1994) 43-46
47. Mantzaris G.J., Petraki K., Archavlis E., et al. A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand J Gastroenterol 36 (2001) 971-974
48. Perencevich M., and Burakoff R. Use of antibiotics in the treatment of inflammatory bowel disease. Inflamm Bowel Dis 12 (2006) 651-664
49. D'Haens G., Lemmens L., Geboes K., et al. Intravenous cyclosporine vs intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 120 (2001) 1323-1329
50. Van Assche G., D'Haens G., Noman M., et al. Randomized, double-blind comparison of 4 mg/kg vs 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 125 (2003) 1025-1031
51. Nye E.B. Gynaecological symptoms following rectal excision. J Obstet Gynaecol Br Commonw 80 (1973) 160-163
52. Roussomoustakaki M., Satsangi J., Welsh K., et al. Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterology 112 (1997) 1845-1853
53. Ho G.T., Nimmo E.R., Tenesa A., et al. Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis. Gastroenterology 128 (2005) 288-296
54. Lennard Jones J.E., Ritchie J.K., Hilder W., and Spicer C.C. Assessment of severity in colitis: a preliminary study. Gut 16 (1975) 579-584
55. Lindgren S.C., Flood L.M., Kilander A.F., et al. Early predictors of glucocorticoid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 10 (1998) 831-835
56. Turner D., Otley A., Mack D.R., et al. Development, validation and evaluation of a Pediatric Ulcerative Colitis Activity Index (PUCAI): a prospective multicenter study. Gastroenterology 133 (2007) 423-432
57. Turner D., Walsh C.M., Chow C., et al. Intravenous corticosteroid therapy for severe pediatric ulcerative colitis: predictors of response and outcome. Gastroenterology 132 Suppl 2 (2007) A-514 (submitted to Gut 2007)
58. Benazzato L., D'Inca R., Grigoletto F., et al. Prognosis of severe attacks in ulcerative colitis: effect of intensive medical treatment. Dig Liver Dis 36 (2004) 461-466
59. Ho G.T., Mowat C., Goddard C.J., et al. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther 19 (2004) 1079-1087
60. Chew C.N., Nolan D.J., and Jewell D.P. Small bowel gas in severe ulcerative colitis. Gut 32 (1991) 1535-1537
61. Almer S., Bodemar G., Franzen L., et al. Use of air enema radiography to assess depth of ulceration during acute attacks of ulcerative colitis. Lancet 347 (1996) 1731-1735
62. Lichtiger S., Present D.H., Kornbluth A., and Gelernt I. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 330 (1994) 1841-1845
63. Hawthorne A.B., Travis S.P.L., and BSG IBD Clinical Trials Network. Outcome of inpatient management of severe ulcerative colitis: a BSG IBD Clinical Trials Network survey. Gut 50 (2002) A16
64. Cohen R.D., Stein R., and Hanauer S.B. Intravenous cyclosporine in ulcerative colitis: a five year experience. Am J Gastroenterol 94 (1999) 1587-1592
65. Campbell S., Travis S.P.L., and Jewell D.P. Ciclosporin use in acute ulcerative colitis: a long-term experience. Eur J Gastroenterol Hepatol 17 (2005) 79-84
66. Moskovitz D.N., Van Assche G., Maenhout B., et al. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol 4 (2006) 760-765
67. Shibolet O., Regushevskaya E., Brezis M., and Soares-Weiser K. Cyclosporine A for induction of remission in severe ulcerative colitis. Cochrane Database Syst Rev 1 (2005) CD004277
68. Ogata H., Matsui T., Nakamura M., et al. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 55 (2006) 1255-1262
69. Webster A., Woodroffe R.C., Taylor R.S., Chapman J.R., and Craig J.C. Tacrolimus vs ciclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 4 (2005) CD003961
70. McAlister V.C., Haddad E., Renouf E., et al. Cyclosporin vs tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis. Am J Transplant 6 (2006) 1578-1585
71. Fellermann K., Tanko Z., Herrlinger K.R., et al. Response of refractory colitis to intravenous or oral tacrolimus (FK506). Inflamm Bowel Dis 8 (2002) 478-479
72. Baumgart D.C., Wiedenmann B., and Dignass A.U. Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment Pharmacol Ther 17 (2003) 1273-1281
73. Hogenauer C., Wenzl H.H., Hinterleitner T.A., and Petritsch W. Effect of oral tacrolimus (FK506) on steroid-refractory moderate/severe ulcerative colitis. Aliment Pharmacol Ther 18 (2003) 415-423
74. Järnerot G., Hertervig E., Friis-Liby I., et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 128 (2005) 1805-1811
75. Seo M., Okada M., Yao T., et al. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 87 (1992) 971-976
76. Sands B.E., Tremaine W.J., Sandborn W.J., et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis 7 (2001) 83-88
77. Kaser A., Mairinger T., Vogel W., and Tilg H. Infliximab in severe steroid-refractory ulcerative colitis: a pilot study. Wien Klin Wochenschr 113 (2001) 930-933
78. Kohn A., Prantera C., Pera A., et al. Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis: result of an open study on 13 patients. Dig Liver Dis 34 (2002) 626-630
79. Rutgeerts P., Sandborn W.J., Feagan B., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 233 (2005) 2462-2473
80. Regueiro M., Curtis J., and Plevy S. Infliximab for hospitalized patients with severe ulcerative colitis. J Clin Gastroenterol 40 (2006) 476-481
81. Jakobovits S., Jewell D.P., and Travis S.P.L. Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006. Aliment Pharmacol Ther 25 (2007) 1055-1060
82. Ferrante M., Vermeire S., Katsanos K.H., et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis 13 (2007) 123-128
83. Lees C.W., Heys D., Ho G., et al. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther 26 (2007) 411-419
84. Colombel J.F., Loftus Jr. E.V., Tremaine W.J., et al. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 99 (2004) 878-883
85. Sheth S.G., and LaMont J.T. Toxic megacolon. Lancet 351 (1998) 509-513
86. Oldfield III E.C. Clostridium difficile-associated diarrhea: resurgence with a vengeance. Rev Gastroenterol Disord 6 (2006) 79-96
87. Goodman M.J., and Truelove S.C. Intensive intravenous regimen for membranous colitis. Br Med J 2 (1976) 354
88. Panos M.Z., Wood M.J., and Asquith P. Toxic megacolon: the knee-elbow position relieves bowel distension. Gut 34 (1993) 1726-1727
89. Hyman N.H., Cataldo P., and Osler T. Urgent subtotal colectomy for severe inflammatory bowel disease. Dis Colon Rectum 48 (2005) 70-73
90. Chen F.C., and Woods R. Pseudomembranous panenteritis and septicaemia in a patient with ulcerative colitis. Aust N Z J Surg 66 (1996) 565-567
91. Annese V., Caruso N., Bisceglia M., et al. Fatal ulcerative panenteritis following colectomy in a patient with ulcerative colitis. Dig Dis Sci 44 (1999) 1189-1195
92. Rubenstein J., Sherif A., Appelman A., and Chey W.D. Ulcerative colitis associated enteritis: is ulcerative colitis always confined to the colon?. J Clin Gastroenterol 38 (2004) 46-51
93. Longo W.E., Virgo K.S., Bahadursingh A.N., and Johnson F.E. Patterns of disease and surgical treatment among United States veterans more than 50 years of age with ulcerative colitis. Am J Surg 186 (2003) 514-518
94. Bojic D., Al-Ali M., Jewell D.P., Nedeljkovic-Protic M., and Travis S.P.L. Pattern and outcome of severe ulcerative colitis: 15 year data. Gut 54 Suppl VII (2005) A155
95. Järnerot G., Lennard-Jones J.E., Bianchi-Porro G., et al. Medical treatment of refractory distal ulcerative colitis. Gastroenterol Int 4 (1991) 93-98
96. Gionchetti P., Rizzello F., Morselli C., and Campieri M. Review article: problematic proctitis and distal colitis. Aliment Pharmacol Ther 20 Suppl 4 (2004) 93-96
97. Hebden J.M., Blackshaw P.E., Perkins A.C., Wilson C.G., and Spiller R.C. Limited exposure of the distal colon to orally-dosed formulation is further exaggerated in active left-sided ulcerative colitis. Aliment Pharmacol Ther 14 (2000) 155-161
98. Järnerot G., Rolny P., and Sandberg-Gertzen H. Intensive intravenous treatment of ulcerative colitis. Gastroenterology 89 (1985) 1005-1013
99. Travis S.P.L. Resistant distal colitis. In: Jewell D.P., Mortensen N.J.M., Steinhart H., Warren B.F., and Pemberton J. (Eds). Challenges in Inflammatory bowel disease. 2nd Ed (2006), Blackwell Publishing 124-143
100. Bjorck S., Dahlstrom A., and Ahlman H. Treatment of distal colitis with local anaesthetic agents. Pharmacol Toxicol 90 (2002) 173-180
101. Saibil F.G. Lidocaine enemas for intractable distal ulcerative colitis: efficacy and safety. Gastroenterology 114 (1998) A1073 (abstract)
102. Arlander E., Ost A., Stahlberg D., and Lofberg R. Ropivacaine gel in active distal ulcerative colitis and proctitis - a pharmacokinetic and exploratory clinical study. Aliment Pharmacol Ther 10 (1996) 73-81
103. Hillingso J.G., Kjeldsen J., Scmidt P.T., et al. Effects of topical ropivacaine on eicosanoids and neurotransmitters in the rectum of patients with distal colitis. Scand J Gastroenterol 37 (2002) 325-329
104. Makins R., and Radford-Smith G. Appendectomy for ulcerative colitis - a therapeutic option?. In: Irving P.M., Rampton D.S., and Shanahan F. (Eds). Clinical dilemmas in inflammatory bowel disease (2006), Blackwell Publishing, Oxford 108-110
105. Forbes A., Britton T.C., House I.M., et al. Safety and efficacy of acetarsol suppositories in unresponsive proctitis. Aliment Pharmacol Ther 3 (1989) 553-556
106. Pullan R.D., Ganesh S., Mani V., et al. Comparison of bismuth citrate and 5-aminosalicylic acid enemas in active distal ulcerative colitis: a controlled trial. Gut 34 (1993) 676-679
107. Khan Z., Macdonald C., Wicks A.C., et al. Use of the 'nutriceutical' bovine colostrum for the treatment of distal colitis: results from an initial study. Aliment Pharmacol Ther 16 (2002) 1917-1922
108. Sandborn W.J., Tremaine W.J., Schroeder K.W., et al. A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. Gastroenterology 106 (1994) 1429-1435
109. Sinha A., Nightingale J.M.D., West K.P., Berlanga-Acosta J., and Playford R.J. Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med 349 (2003) 350-357
110. Kono T., Nomura M., Kasai S., and Kogho Y. Effect of ecabet sodium enema on mildly to moderately active ulcerative proctosigmoiditis: an open-label study. Am J Gastroenterol 96 (2001) 793-797
111. Jarlov A.E., Munkholm P., Schmidt P.N., et al. Treatment of active distal ulcerative colitis with immunoglobulin G enemas. Aliment Pharmacol Ther 7 (1993) 561-565
112. Schreiber S., Heinig T., Thiele H.G., and Raedler A. Immunoregulatory role of interleukin-10 in patients with inflammatory bowel disease. Gastroenterology 108 (1995) 1434-1444
113. Yamamoto T., Umegae S., Kitagawa T., et al. Granulocyte and monocyte adsorptive apheresis in the treatment of active distal ulcerative colitis: a prospective, pilot study. Aliment Pharmacol Ther 20 (2004) 783-792
114. Pullan R.D., Rhodes J., Ganesh S., et al. Transdermal nicotine for active ulcerative colitis. N Engl J Med 330 (1994) 811-895
115. Thomas G.A.O., Rhodes J., Mani V., et al. Transdermal nicotine as maintenance therapy for ulcerative colitis. N Engl J Med 332 (1995) 988-992
116. Thomas G.A.O., Rhodes J., Ragunath K., et al. Transdermal nicotine compared with oral prednisolone therapy for active ulcerative colitis. Eur J Gastroenterol Hepatol 8 (1996) 769-776
117. Sandborn W.J., Tremaine W., Offord K.P., et al. A randomized, double-blind, placebo controlled trial of transdermal nicotine for mildly to moderately active ulcerative colitis. Ann Intern Med 126 (1997) 364-371
118. Guslandi M., Frego R., Vitale E., and Testoni P.A. Distal ulcerative colitis refractory to rectal mesalamine: role of transdermal nicotine vs oral mesalamine. Can J Gastroenterol 16 (2002) 293-296
119. Sandborn W.J., Tremaine W.J., Leighton J.A.S., et al. Nicotine tartrate liquid enemas for mildly to moderately active left-sided ulcerative colitis unresponsive to first-line therapy: a pilot study. Aliment Pharmacol Ther 11 (1997) 663-671
120. Green J.T., Thomas G.A.O., Rhodes J., et al. Nicotine enemas for active ulcerative colitis - a pilot study. Aliment Pharmacol Ther 11 (1997) 859-863
121. Gasbarrini G., Mingrone G., Giancaterini A., et al. Effects of propionyl-l-carnitine topical irrigation in distal ulcerative colitis: a preliminary report. Hepatogastroenterolgy 50 (2003) 1385-1389
122. Furuta R., Ando T., Watanabe O., et al. Rebamipide enema therapy as a treatment for patients with active distal ulcerative colitis. J Gastroenterol Hepatol 22 (2007) 261-267
123. Senagore A.J., MacKeigan J.M., Scheider M., and Ebrom J.S. Short-chain fatty acid enemas: a cost-effective alternative in the treatment of non-specific proctosigmoiditis. Dis Colon Rectum 35 (1992) 923-927
124. Vernia P., Marcheggiano A., Caprilli R., et al. Short-chain fatty acid topical treatment in distal ulcerative colitis. Aliment Pharmacol Ther 9 (1995) 309-313
125. Patz J., Jacobsohn W.Z., Gottschalk-Sabag S., Zeides S., and Braverman D.Z. Treatment of refractory distal colitis with short-chain fatty acid enemas. Am J Gastroenterol 91 (1996) 731-734
126. Breuer R.I., Soergel K.H., Lashner B.A., et al. Short-chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomized, placebo-controlled trial. Gut 40 (1997) 485-491
127. Scheppach W., and Group G.A. Treatment of distal ulcerative colitis with short-chain fatty acid enemas. A placebo-controlled trial Dig Dis Sci 41 (1996) 2254-2259
128. Steinhart A.H., Hiruki T., Brezezinski A., and Baker J.P. Treatment of left-sided ulcerative colitis with butyrate enemas: a controlled trial. Aliment Pharmacol Ther 10 (1996) 729-736
129. Riley S.A., Gupta I., and Mani V. A comparison of sucralfate and prednisolone enemas in the treatment of active distal ulcerative colitis. Scand J Gastroenterol 24 (1989) 1014-1018
130. Campieri M., Gionchetti P., Belluzzi A., et al. Sucralfate, 5-aminosalicylic acid and placebo enemas in the treatment of distal ulcerative colitis. Eur J Gastroenterol & Hepatol 3 (1991) 41-44
131. Ardizzone S., Petrillo M., Antonacci C.M., and Bianchi Porro G. Sucralfate and hydrocortisone enemas in the treatment of active ulcerative proctitis - a randomised single-blind comparative study. Aliment Pharmacol Ther 10 (1996) 957-960
132. Wright J.P., Winter T.A., Candy S., and Marks I.S. Sucralfate and methylprednisolone enemas in active ulcerative colitis: a prospective, single-blind study. Dig Dis Sci 44 (1999) 1899-1901
133. van Outryve M., Huble F., van Eeghem P., et al. Comparison of Ridrogel vs prednisolone, both administered rectally, for the treatment of active ulcerative colitis. Gastroenterology 110 (1996) A1035 (abstract)
134. Auwerda J.J., Zijlstra F.J., Tak C.J., et al. Ridogrel enemas in distal ulcerative colitis. Eur J Gastroenterol Hepatol 13 (2001) 397-400
135. Ben-Ayre E., Goldi E., Wengrower D., et al. Wheat grass juice in the treatment of active distal ulcerative colitis: a randomised double-blind placebo controlled trial. Scand J Gastroenterol 37 (2002) 444-449
136. Brunel M., Penne C., Tiret E., Balladur P., and Parc R. Restorative proctocolectomy for distal ulcerative colitis. Gut 45 (1999) 542-545
137. Ardizzone S., Maconi G., Russo A., et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 55 (2006) 47-53
138. Sandborn W.J., and Hanauer S.B. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther 17 (2003) 29-42
139. Klotz U. Colonic targeting of aminosalicylates for the treatment of ulcerative colitis. Dig Liver Dis 37 (2005) 381-388
140. Desreumaux P., and Ghosh S. Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence. Aliment Pharmacol Ther 24 Suppl 1 (2006) 2-9
141. Schroeder K.W., Tremaine W.J., and Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 317 (1987) 1625-1629
142. Sninsky C.A., Cort D.H., Shanahan F., et al. Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study. Ann Intern Med 115 (1991) 30-35
143. Hanauer S., Schwartz J., Robinson M., et al., Pentasa Study Group. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Am J Gastroenterol 88 (1993) 1188-1197
144. Meyers S., Sachar D.B., Present D.H., and Janowitz H.D. Olsalazine sodium in the treatment of ulcerative colitis among patients intolerant of sulfasalazine. A prospective, randomized, placebo-controlled, double-blind, dose-ranging clinical trial. Gastroenterology 93 (1987) 1255-1262
145. Hetzel D.J., Shearman D.J., Labrooy J., et al. Olsalazine in the treatment of active ulcerative colitis: a placebo controlled clinical trial and assessment of drug disposition. Scand J Gastroenterol Suppl 148 (1988) 61-69
146. Feurle G.E., Theuer D., Velasco S., et al. Olsalazine vs placebo in the treatment of mild to moderate ulcerative colitis: a randomised double blind trial. Gut 30 (1989) 1354-1361
147. Zinberg J., Molinas S., and Das K.M. Double-blind placebo-controlled study of olsalazine in the treatment of ulcerative colitis. Am J Gastroenterol 85 (1990) 562-566
148. Sutherland L., Robinson M., Onstad G., et al. A double-blind, placebo-controlled, multicenter study of the efficacy and safety of 5-aminosalicylic acid tablets in the treatment of ulcerative colitis. Can J Gastroenterol 4 (1990) 463-467
149. Green J.R., Lobo A.J., Holdsworth C.D., et al., The Abacus Investigator Group. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. Gastroenterology 114 (1998) 15-22
150. Levine D.S., Riff D.S., Pruitt R., et al. A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. Am J Gastroenterol 97 (2002) 1398-1407
151. Pruitt R., Hanson J., Safdi M., et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. Am J Gastroenterol 97 (2002) 3078-3086
152. Forbes A., Al-Damluji A., Ashworth S., et al. Multicentre randomized-controlled clinical trial of Ipocol, a new enteric-coated form of mesalazine, in comparison with Asacol in the treatment of ulcerative colitis. Aliment Pharmacol Ther 21 (2005) 1099-1104
153. Forbes A. Review article: oral, modified-release mesalazine formulations - proprietary vs generic. Aliment Pharmacol Ther 17 (2003) 1207-1214
154. Loftus Jr. E.V., Kane S.V., and Bjorkman D. Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. Aliment Pharmacol Ther 19 (2004) 179-189
155. Van Staa T.P., Travis S., Leufkens H.G., and Logan R.F. 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study. Gastroenterology 126 (2004) 1733-1739
156. Truelove S.C., and Witts L.J. Cortisone in ulcerative colitis: preliminary report on a therapeutic trial. Br Med J ii (1954) 375-378
157. Ho G.T., Chiam P., Drummond H., et al. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of a 5-year UK inception cohort. Aliment Pharmacol Ther 24 (2006) 319-330
158. Travis S.P., Stange E.F., Lémann M., et al. European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut 55 Suppl 1 (2006) i16-i35
159. Lawson M.M., Thomas A.G., and Akobeng A.K. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 3 (2006) CD005112
160. Sands B.E., Tremaine W.J., Sandborn W.J., et al. Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study. Infamm Bowel Dis 7 (2001) 83-88
161. Probert C.S., Hearing S.D., Schreiber S., et al. Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial. Gut 52 (2003) 998-1002
162. Ochsenkuhn T., Sackmann M., and Goke B. Infliximab for acute, not steroid-refractory ulcerative colitis: a randomized pilot study. Eur J Gastroenterol Hepatol 16 (2004) 1167-1171
163. Armuzzi A., De Pascalis B., Lupascu A., et al. Infliximab in the treatment of steroid-dependent ulcerative colitis. Eur Rev Med Pharmacol Sci 8 (2004) 231-233
164. Lichtenstein G.R., Feagan B.G., Cohen R.D., et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 4 (2006) 621-630
165. Caspersen S, Elkjaer M, Riis L, et al. Infliximab treatment in inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow up on malignancy and mortality. Clin Gastroenterol Hepatol 2008; in press.
166. Sandborn W.J., Rutgeerts P., Feagan B.G., et al. Inflicimab reduces colectomy in patients with moderate-to-severe ulcerative colitis: colectomy analysis from ACT1 and ACT 2. Gut 56 suppl III (2007) A26
167. Targan S.R., Salzberg B.A., Mayer L., et al. A phase I-II study: multiple dose levels of visilizumab are well tolerated and produce rapid and sustained improvement in ulcerative colitis patients refractory to treatment with intravenous steroids (IVSR-UC). Gastroenterology 128 Suppl 2 (2005) A-75
168. Van Deventer S.J., Volfova M., Flisiak R., et al. A phase 2 dose-ranging, double blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Gastroenterology 128 Suppl 2 (2005) A-74
169. Miner P.B., Nichols T., Schwartz H., et al. A phase 2 trial to assess the safety and efficacy of two dose formulations of alicaforsen enema compared with mesalamine enema for acute ulcerative colitis. Gastroenterology 128 Suppl 2 (2005) A-74
170. Feagan B.G., Greenberg G.R., Wild G., et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 352 (2005) 2499-2507
171. Creed T.J., Probert C.S., Norman M.N., et al. Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease. Aliment Pharmacol Ther 23 (2006) 1435-1442
172. Van Assche G., Sandborn W.J., Feagan B.G., et al. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial. Gut 55 (2006) 1568-1574
173. D'Haens G., and Daperno M. Advances in biologic therapy for ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep 8 (2006) 506-512
174. Hanauer S.B., Rutgeerts P., Clark M., et al. AGA institute consensus development conference on the use of biologics in the treatment of inflammatory bowel disease. Gastroenterology 133 (2007) 312-339
175. Ghosh S., Chaudhary R., Carpani M., and Playford R.J. Is thiopurine therapy in ulcerative colitis as effective as in Crohn's disease?. Gut 55 (2006) 6-8
176. Jewell D.P., and Truelove S.C. Azathioprine in ulcerative colitis: final report on a controlled therapeutic trial. Br Med J 4 5945 (1974) 627-630
177. Caprilli R., Carratu R., Babbini M., et al. A double-blind comparison of the effectiveness of azathioprine and sulfasalazine in idiopathic proctocolitis. Dig Dis Sci 20 (1975) 115-120
178. Rosenberg J.L., Wall A.J., Levin B., Binder H.J., and Kirsner J.B. A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology 69 (1975) 96-99
179. Kirk P., and Lennard-Jones J.E. Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J 284 (1982) 1291-1292
180. Holtmann M.H., Krummenauer F., Claas C., et al. Long-term effectiveness of azathioprine in IBD beyond 4 years: a European multicenter study in 1176 patients. Dig Dis Sci 51 (2006) 1516-1524
181. Hindorf U., Lindqvist M., Peterson C., et al. Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease. Gut 55 (2006) 1423-1431
182. Oren R., Arber N., Odes S., et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 110 (1996) 1416-1421
183. Mate-Jimenez J., Hermida C., Cantero-Perona J., et al. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol 12 (2000) 1227-1233
184. Kozarek R.A., Patterson D.J., Gelfand M.D., et al. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 110 (1989) 353-356
185. Lichtenstein G.R., Abreu M.T., Cohen R., and Tremaine W. AGA Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 130 (2006) 940-987
186. Grant D., Kneteman N., Tchervenkov J., et al. Peak cyclosporine level (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of Neoral and Sandimune for liver transplant (NOF8). Transplantation 67 (1999) 1133-1137
187. Arts J., D'Haens G., Zeegers M., et al. Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis. Inflamm Bowel Dis 10 (2004) 73-78
188. Ohkusa T., Nomura T., Terai T., et al. Effectiveness of antibiotic combination therapy in patients with active ulcerative colitis: a randomized, controlled pilot trial with long-term follow-up. Scand J Gastroenterol 40 (2005) 1334-1342
189. Summers R.W., Elliott D.E., Urban Jr. J.F., Thompson R.A., and Weinstock J.V. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology 128 (2005) 825-832
190. Malhotra S., Bhasin D., Shafiq N., and Pandhi P. Drug treatment of ulcerative colitis: unfractionated heparin, low molecular weight heparins and beyond. Expert Opin Pharmacother 5 (2004) 329-334
191. Tilg H., Vogelsang H., Ludwiczek O., et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut 52 (2003) 1728-1733
192. Sawada K., Muto T., Shimoyama T., et al. Multicenter randomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr Pharm Des 9 (2003) 307-321
193. Sawada K., Kusugami K., Suzuki Y., et al. Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am J Gastroenterol 100 (2005) 1362-1369
194. Sandborn W.J. Preliminary data on the use of apheresis in inflammatory bowel disease. Inflamm Bowel Dis 12 Suppl 1 (2006) S15-S21
195. Meyers S., and Janowitz H.D. The natural history of ulcerative colitis: an analysis of the placebo response. J Clin Gastroenterol 11 (1989) 33-37
196. Jess T., Riis L., Vind I., et al. Changes in clinical characteristics, course, and prognosis of inflammatory bowel disease during the last 5 decades: a population-based study from Copenhagen, Denmark. Inflamm Bowel Dis 13 (2007) 481-489
197. Leo S., Leandro G., Di Matteo G., Caruso M.L., and Lorusso D. Ulcerative colitis in remission: it is possible to predict the risk of relapse?. Digestion 44 (1989) 217-221
198. Riley S.A., Mani V., Goodman M.J., and Lucas S. Why do patients with ulcerative colitis 'relapse'?. Gut 31 (1990) 179-183
199. Bitton A., Peppercorn M.A., Antonioli D.A., et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 120 (2001) 13-20
200. Bitton A., Sewitch M.J., Peppercorn M.A., et al. Psychosocial determinants of relapse in ulcerative colitis: a longitudinal study. Am J Gastroenterol 98 (2003) 2203-2208
201. Vidal A., Gómez-Gil E., Sans M., et al. Life events and inflammatory bowel disease relapse: a prospective study of patients enrolled in remission. Am J Gastroenterol 101 (2006) 775-781
202. Wright R., and Truelove S.C. Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets. Am J Dig Dis 11 (1966) 847-857
203. Riley S.A., Mani V., Goodman M.J., Dutt S., and Herd M.E. Microscopic activity in ulcerative colitis: what does it mean?. Gut 32 (1991) 174-178
204. Levenstein S., Prantera C., Varvo V., et al. Stress and exacerbation in ulcerative colitis: a prospective study of patients enrolled in remission. Am J Gastroenterol 95 (2000) 1213-1221
205. Kane S., Huo D., Aikens J., and Hanauer S. Medication non-adherence and the outcomes of patients with quiescent ulcerative colitis. Am J Med 114 (2003) 39-43
206. Faubion Jr. W.A., Loftus Jr. E.V., Harmsen W.S., Zinsmeister A.R., and Sandborn W.J. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 121 (2001) 255-260
207. Sutherland L., and Macdonald J.K. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 19 (2006) CD000544
208. Misiewicz J.J., Lennard-Jones J., Connell A.M., Baron J.H., and Avery Jones H. Controlled trial of sulphasalazine in maintenance therapy for ulcerative colitis. Lancet 1 (1965) 185-188
209. Dissanayake A.S., and Truelove S.C. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin). Gut 14 (1973) 923-926
210. Riis P., Anthonisen P., Wulff H.R., et al. Prophylactic effect of salazosulphapyridine in ulcerative colitis during long-term treatment. A double-blind trial on patients asymptomatic for one year. Scand J Gastroenterol 8 (1973) 71-74
211. Sandberg-Gertzen H., Jarnerot G., and Kraaz W. Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties. Gastroenterology 90 (1986) 1024-1030
212. Wright J.P., O'Keefe E.A., Cuming L., and Jaskiewicz K. Olsalazine in maintenance of clinical remission in patients with ulcerative colitis. Dig Dis Sci 38 (1993) 1837-1842
213. Miner P., Hanauer S., Robinson M., Schwartz J., Arora S., and Pentasa UC Maintenance Study Group. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Dig Dis Sci 40 (1995) 296-304
214. Hanauer S., Sninsky C.A., Robinson M., et al. An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. Ann Intern Med 124 (1996) 204-211
215. Hawkey C.J., Dube L.M., Rountree L.V., Linnen P.J., Lancaster J.F., and The European Zileuton Study Group For Ulcerative Colitis. A trial of zileuton vs mesalazine or placebo in the maintenance of remission of ulcerative colitis. Gastroenterology 112 (1997) 718-724
216. Marteau P., Crand J., Foucault M., and Rambaud J.C. Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised, double-blind, placebo-controlled multicentre study. Gut 42 (1998) 195-199
217. Moody G.A., Eaden J.A., Helyes Z., and Mayberry J.F. Oral or rectal administration of drugs in IBD?. Aliment Pharmacol Ther 11 (1997) 999-1000
218. Casellas F., Vaquero E., Armengol J.R., and Malagelada J.R. Practicality of 5-aminosalicylic suppositories for long-term treatment of inactive distal ulcerative colitis. Hepatogastroenterology 46 (1999) 2343-2346
219. Paoluzi O.A., Iacopini F., Pica R., et al. Comparison of two different daily dosages (2.4 vs 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. Aliment Pharmacol Ther 21 (2005) 1111-1119
220. Travis S.P.L. What is the optimal dosage of mesalazine to maintain remission in patients with ulcerative colitis?. Nat Clin Pract Gastroenterol Hepatol 2 (2005) 564-565
221. Fockens P., Mulder C.J., Tytgat G.N., et al., Dutch Pentasa Study Group. Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Eur J Gastroenterol Hepatol 7 (1995) 1025-1030
222. Hanauer S.B. Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis. Aliment Pharmacol Ther 24 Suppl 3 (2006) 37-40
223. Courtney M.G., Nunes D.P., Bergin C.F., et al. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Lancet 339 (1992) 1279-1281
224. Kane S., Cohen R.D., Aikens J.E., and Hanauer S.B. Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 96 (2001) 2929-2933
225. Kane S., Huo D., and Magnanti K. A pilot feasibility study of once daily vs conventional dosing mesalamine for maintenance of ulcerative colitis. Clin Gastroenterol Hepatol 1 (2003) 170-173
226. Dignass A., Vermeire S., Adamek H., et al. Improved remission rates from once- vs twice-daily mesalazine (Pentasa®) granules for the maintenance of remission in ulcerative colitis: results from a multinational randomised controlled trial. UEGW (2007)
227. Kruis W., Gorelov A., Kiudelis G., et al. Once daily dosing of 3 g mesalamine (Salofalk® granules) is therapeutic equivalent to a three-times daily dosing of 1 g mesalamine for the treatment of active ulcerative colitis. Gastroenterology 132 Suppl 4 (2007) A-130
228. Sutherland L.R., and Martin F. 5-Aminosalicylic acid enemas in treatment of distal ulcerative colitis and proctitis in Canada. Dig Dis Sci 32 (1987) 64S-66S
229. Biddle W.L., Greenberger N.J., Swan J.T., McPhee M.S., and Miner Jr. P.B. 5-Aminosalicylic acid enemas: effective agent in maintaining remission in left-sided ulcerative colitis. Gastroenterology 94 (1988) 1075-1079
230. D'Arienzo A., Panarese A., D'Armiento F.P., et al. 5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: a double-blind placebo-controlled clinical trial. Am J Gastroenterol 85 (1990) 1079-1082
231. D'Albasio G., Trallori G., Ghetti A., et al. Intermittent therapy with high-dose 5-aminosalicylic acid enemas for maintaining remission in ulcerative proctosigmoiditis. Dis Colon Rectum 33 (1990) 394-397
232. Miner P., Daly R., Nester T., et al. The effect of varying dose intervals of mesalamine enemas for the prevention of relapse in distal ulcerative colitis. Gastroenterology 106 (1994) A736
233. Andreoli A., Spinella S., Levenstein S., and Prantera C. 5-ASA enema vs oral sulphasalazine in maintaining remission in ulcerative colitis. Ital J Gastroenterol 26 (1994) 121-125
234. Mantzaris G.J., Hatzis A., Petraki K., Spiliadi C., and Triantaphyllou G. Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis. Dis Colon Rectum 37 (1994) 58-62
235. D'Albasio G., Pacini F., Camarri E., et al. Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study. Am J Gastroenterol 92 (1997) 1143-1147
236. D'Albasio G., Paoluzi P., Campieri M., et al., The Italian IBD Study Group. Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial. Am J Gastroenterol 93 (1998) 799-803
237. Hanauer S., Good L.I., Goodman M.W., et al. Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis. Am J Gastroenterol 95 (2000) 1749-1754
238. Yokoyama H., Takagi S., Kuriyama S., et al. Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study. Inflamm Bowel Dis 13 (2007) 1115-1120
239. Azad Khan A.K., Piris J., and Truelove S.C. Optimum dose of sulphasalazine for maintenance treatment of ulcerative colitis. Gut 21 (1980) 232-240
240. Andreoli A.C.R., Trotti R., Berri F., and Prantera C. 5-aminosalicylic-acid (5-ASA) vs salazopyrin (SASP) in the oral treatment of active ulcerative colitis (UC) and in remission (abstract). Clinical Controversies in Inflammatory Bowel Disease 170 (1987)
241. Ireland A., Mason C.H., and Jewell D.P. Controlled trial comparing olsalazine and sulphasalazine for the maintenance treatment of ulcerative colitis. Gut 29 (1988) 835-837
242. Riley S.A., Mani V., Goodman M.J., et al. Comparison of delayed-release 5-aminosalicylic acid (mesalamine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology 94 (1988) 1383-1389
243. Mulder C.J., Tytgat G.N., Weterman I.T., et al. Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. Gastroenterology 95 (1988) 1449-1453
244. McIntyre P.B., Rodrigues C.A., Lennard-Jones J.E., et al. Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine. Aliment Pharmacol Ther 2 (1988) 237-243
245. Rutgeerts P. Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. International Study Group. Aliment Pharmacol Ther 3 (1989) 183-191
246. Kiilerich S., Ladefoged K., Rannem T., and Ranlov P.J. Prophylactic effects of olsalazine v sulphasalazine during 12 months maintenance treatment of ulcerative colitis. The Danish Olsalazine Study Group. Gut 33 (1992) 252-255
247. Rijk M.C., van Lier H.J., van Tongeren J.H., and The Ulcerative Colitis Multicenter Study Group. Relapse-preventing effect and safety of sulfasalazine and olsalazine in patients with ulcerative colitis in remission: a prospective, double-blind, randomized multicenter study. Am J Gastroenterol 87 (1992) 438-442
248. Travis S.P.L., Tysk C., de Silva H.J., et al. Optimum dose of olsalazine for maintaining remission in ulcerative colitis. Gut 35 (1994) 1282-1286
249. Ardizzone S., Petrillo M., Molteni P., Desideri S., and Bianchi Porro G. Coated oral 5-aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. A double-blind study. J Clin Gastroenterol 21 (1995) 287-289
250. Kruis W., Judmaier G., Kayasseh L., et al. Double-blind dose-finding study of olsalazine vs sulphasalazine as maintenance therapy for ulcerative colitis. Eur J Gastroenterol Hepatol 7 (1995) 391-396
251. Nilsson A., Danielsson A., Lofberg R., et al. Olsalazine vs sulphasalazine for relapse prevention in ulcerative colitis: a multicenter study. Am J Gastroenterol 90 (1995) 381-387
252. Hawthorne A.B., Logan R.F., Hawkey C.J., et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 305 (1992) 20-22
253. Sood A., Midha V., Sood N., and Kaushal V. Role of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trial. Indian J Gastroenterol 19 (2000) 14-16
254. Sood A., Kaushal V., Midha V., et al. The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis. J Gastroenterol 37 (2002) 270-274
255. Sood A., Midha V., Sood N., and Avasthi G. Azathioprine vs sulfasalazine in maintenance of remission in severe ulcerative colitis. Indian J Gastroenterol 22 (2003) 79-81
256. Timmer A., McDonald J.W., and Macdonald J.K. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 24 (2007) CD000478
257. Adler D.J., and Korelitz B.I. The therapeutic efficacy of 6-mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol 85 (1990) 717-722
258. Steinhart A.H., Baker J.P., Brzezinski A., and Prokipchuk E.J. Azathioprine therapy in chronic ulcerative colitis. J Clin Gastroenterol 12 (1990) 271-275
259. Lobo A.J., Foster P.N., Burke D.A., Johnston D., and Axon A.T. The role of azathioprine in the management of ulcerative colitis. Dis Colon Rectum 33 (1990) 374-377
260. George J., Present D.H., Pou R., Bodian C., and Rubin P.H. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol 91 (1996) 1711-1714
261. Ardizzone S., Molteni P., Imbesi V., et al. Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. J Clin Gastroenterol 25 (1997) 330-333
262. Khan Z.H., Mayberry J.F., Spiers N., and Wicks A.C. Retrospective case series analysis of patients with inflammatory bowel disease on azathioprine. A district general hospital experience. Digestion 62 (2000) 249-254
263. Fraser A.G., Orchard T.R., and Jewell D.P. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 50 (2002) 485-489
264. Marion J.F., and Present D. 6-MP maintains cyclosporine induced response in patients with severe ulcerative colitis (abstract). Am J Gastroenterol 91 (1996) 1975
265. Fernandez-Banares F., Bertran X., Esteve-Comas M., et al. Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. Am J Gastroenterol 91 (1996) 2498-2499
266. Actis G.C., Bresso F., Astegiano M., et al. Safety and efficacy of azathioprine in the maintenance of ciclosporin-induced remission of ulcerative colitis. Aliment Pharmacol Ther 15 (2001) 1307-1311
267. Domenech E., Garcia-Planella E., Bernal I., et al. Azathioprine without oral ciclosporin in the long-term maintenance of remission induced by intravenous ciclosporin in severe, steroid-refractory ulcerative colitis. Aliment Pharmacol Ther 16 (2002) 2061-2065
268. Baert F., Noman M., Vermeire S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 348 (2003) 601-608
269. Vermeire S., Noman M., Van Assche G., et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 56 (2007) 1226-1231
270. Van Assche G., Paintaud G., D'Haens G., et al. Continuation of immunosuppression is not required to maintain adequate infliximab efficacy in patients with Crohn's disease but may improve pharmacokinetics. Gastroenterology 130 (2006) A142
271. Mackey A.C., Green L., Liang L.C., et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 44 (2007) 265-267
272. Travis S.P.L. Infliximab and azathioprine: bridge or parachute?. Gastroenterology 130 (2006) 1354-1357
273. Lémann M., Mary J.Y., Duclos B., et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 130 (2006) 1054-1061
274. Gustavsson A., Järnerot G., Hertevig E., et al. A 2-year follow-up of the Swedish-Danish Infliximab/placebo trial in steroid resistant acute ulcerative colitis. Gastroenterology 132 Suppl 2: (2007) A983
275. Kruis W., Schutz E., Fric P., et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 11 (1997) 853-858
276. Rembacken B.J., Snelling A.M., Hawkey P.M., Chalmers D.M., and Axon A.T.R. Non-pathogenic Escherichia coli vs mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354 (1999) 635-639
277. Kruis W., Fric P., Pokrotnieks J., et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53 (2004) 1617-1623
278. Ishikawa H., Imaoka A., Umesaki Y., et al. Randomized controlled trial of the effect of bifidobacterium-fermented milk on ulcerative colitis. Gastroenterology 118 Suppl 2 (2000) A779
279. Zocco M.A., dal Verme L.Z., Cremonini F., et al. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 23 (2006) 1567-1574
280. Turunen U.M., Farkkila M.A., Hakala K., et al. Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology 115 (1998) 1072-1078
281. Present D.H. Ciprofloxacin as a treatment for ulcerative colitis - not yet. Gastroenterology 115 (1998) 1289-1291
282. Gilat T., Leichtman G., Delpre G., et al. A comparison of metronidazole and sulfasalazine in the maintenance of remission in patients with ulcerative colitis. J Clin Gastroenterol 11 (1989) 392-395
283. Fraser A.G., Morton D., McGovern D., Travis S., and Jewell D.P. The efficacy of methotrexate for maintaining remission in inflammatory bowel disease. Aliment Pharmacol Ther 16 (2002) 693-697
284. Paoluzi O.A., Pica R., Marcheggiano A., et al. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. Aliment Pharmacol Ther 16 (2002) 1751-1759
285. Siveke J.T., and Folwaczny C. Methotrexate in ulcerative colitis. Aliment Pharmacol Ther 17 (2003) 479-480
286. Cummings J.R.F., Herrlinger K.R., Travis S.P.L., et al. Oral methotrexate in ulcerative colitis. Aliment Pharmacol Ther 21 (2005) 385-389
287. MacLean C.H., Mojica W.A., Newberry S.J., et al. Systematic review of the effects of n-3 fatty acids in inflammatory bowel disease. Am J Clin Nutr 82 (2005) 611-619
288. Almallah Y.Z., El-Tahir A., Heys S.D., Richardson S., and Eremin O. Distal procto-colitis and n-3 polyunsaturated fatty acids: the mechanism(s) of natural cytotoxicity inhibition. Eur J Clin Invest 30 (2000) 58-65
289. Lorenz R., Weber P.C., Szimnau P., et al. Supplementation with n-3 fatty acids from fish oil in chronic inflammatory bowel disease - a randomized, placebo-controlled, double-blind cross-over trial. J Intern Med Suppl 225 (1989) 225-232
290. Aslan A., and Triadafilopoulos G. Fish oil fatty acid supplementation in active ulcerative colitis: a double-blind, placebo-controlled, crossover study. Am J Gastroenterol 87 (1992) 432-437
291. Stenson W.F., Cort D., Rodgers J., et al. Dietary supplementation with fish oil in ulcerative colitis. Ann Intern Med 116 (1992) 609-614
292. Hawthorne A.B., Daneshmend T.K., Hawkey C.J., et al. Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial. Gut 33 (1992) 922-928
293. Greenfield S.M., Green A.T., Teare J.P., et al. A randomized controlled study of evening primrose oil and fish oil in ulcerative colitis. Aliment Pharmacol Ther 7 (1993) 159-166
294. Loeschke K., Ueberschaer B., Pietsch A., et al. n-3 fatty acids only delay early relapse of ulcerative colitis in remission. Dig Dis Sci 41 (1996) 2087-2094
295. Mantzaris G.J., Archavlis E., Zografos C., et al. A prospective, randomized, placebo-controlled study of fish oil in ulcerative colitis. Hellenic J Gastroenterol 9 (1996) 138-141
296. Almallah Y.Z., Richardson S., O'Hanrahan T., et al. Distal proctocolitis, natural cytotoxicity, and essential fatty acids. Am J Gastroenterol 93 (1998) 804-809
297. Middleton S.J., Naylor S., Woolner J., and Hunter J.O. A double-blind, randomized, placebo-controlled trial of essential fatty acid supplementation in the maintenance of remission of ulcerative colitis. Aliment Pharmacol Ther 16 (2002) 1131-1135
298. Turner D., Steinhart A., and Griffiths A. Omega 3 fatty acids (fish oil) for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 3 (2007) CD006443
299. Koutroubakis I.E., and Vlachonikolis I.G. Appendectomy and the development of ulcerative colitis: results of a metaanalysis of published case-control studies. Am J Gastroenterol 95 (2000) 171-176
300. Andersson R.E., Olaison G., Tysk C., et al. Appendectomy and protection against ulcerative colitis. N Engl J Med 344 (2001) 808-814
301. Cosnes J., Carbonnel F., Beaugerie L., et al. Effects of appendicectomy on the course of ulcerative colitis. Gut 51 (2002) 803-807
302. Radford-Smith G.L., Edwards J.E., et al. Protective role of appendicectomy on onset and severity of ulcerative colitis and Crohn's disease. Gut 51 (2002) 808-813
303. Florin T.H., Pandeya N., and Radford-Smith G.L. Epidemiology of appendicectomy in primary sclerosing cholangitis and ulcerative colitis: its influence on the clinical behaviour of these diseases. Gut 53 (2004) 973-979
304. Ardizzone S., Petrillo M., Imbesi V., et al. Is maintenance therapy always necessary for patients with ulcerative colitis in remission?. Aliment Pharmacol Ther 13 (1999) 373-379
305. Berndtsson I., Lindholm E., and Ekman I. Thirty years of experience living with a continent ileostomy. J Wound Ostomy Continence Nurs 32 (2005) 321-326
306. Richards D.M., Hughes S.A., Irving M.H., and Scott N.A. Patient quality of life after successful restorative proctocolectomy is normal. Colorectal Dis 3 (2001) 223-226
307. Berndtsson I., and Oresland T. Quality of life before and after proctocolectomy and IPAA in patients with ulcerative proctocolitis - a prospective study. Colorectal Dis 5 (2003) 173-179
308. Alves A., Panis Y., Bouhnik Y., et al. Subtotal colectomy for severe acute colitis: a 20-year experience of a tertiary care center with an aggressive and early surgical policy. J Am Coll Surg 197 (2003) 379-385
309. Berg D.F., Bahadursingh A.M., Kaminski D.L., and Longo W.E. Acute surgical emergencies in inflammatory bowel disease. Am J Surg 184 (2002) 45-51
310. Hyman N.H., Cataldo P., and Osler T. Urgent subtotal colectomy for severe inflammatory bowel disease. Dis Colon Rectum 48 (2005) 70-73
311. McKee R.F., Keenan R.A., and Munro A. Colectomy for acute colitis: is it safe to close the rectal stump?. Int J Colorectal Dis 10 (1995) 222-224
312. Carter F.M., McLeod R.S., and Cohen Z. Subtotal colectomy for ulcerative colitis: complications related to the rectal remnant. Dis Colon Rectum 34 (1991) 1005-1009
313. Annibali R., Oresland T., and Hulten L. Does the level of stapled ileoanal anastomosis influence physiologic and functional outcome?. Dis Colon Rectum 37 (1994) 321-329
314. Lovegrove R.E., Constantinides V.A., Heriot A.G., et al. A comparison of hand-sewn vs stapled ileal pouch anal anastomosis (IPAA) following proctocolectomy: a meta-analysis of 4183 patients. Ann Surg 244 (2006) 18-26
315. Gullberg K., Lindforss U., Zetterquist H., et al. Cancer risk assessment in long-standing pouchitis. DNA aberrations are rare in transformed neoplastic pelvic pouch mucosa. Int J Colorectal Dis 17 (2002) 92-97
316. Borjesson L., Willen R., Haboubi N., Duff S.E., and Hulten L. The risk of dysplasia and cancer in the ileal pouch mucosa after restorative proctocolectomy for ulcerative proctocolitis is low: a long-term term follow-up study. Colorectal Dis 6 (2004) 494-498
317. Scarpa M., van Koperen P.J., Ubbink D.T., Hommes D.W., Ten Kate F.J., and Bemelman W.A. Systematic review of dysplasia after restorative proctocolectomy for ulcerative colitis. Br J Surg 94 (2007) 534-545
318. Heuschen U.A., Hinz U., Allemeyer E.H., et al. One- or two-stage procedure for restorative proctocolectomy: rationale for a surgical strategy in ulcerative colitis. Ann Surg 234 (2001) 788-794
319. Garcia-Botello S.A., Garcia-Armengol J., Garcia-Granero E., et al. A prospective audit of the complications of loop ileostomy construction and takedown. Dig Surg 21 (2004) 440-446
320. Hainsworth P.J., and Bartolo D.C. Selective omission of loop ileostomy in restorative proctocolectomy. Int J Colorectal Dis 13 (1998) 119-123
321. Galandiuk S., Wolff B.G., Dozois R.R., and Beart Jr. R.W. Ileal pouch-anal anastomosis without ileostomy. Dis Colon Rectum 34 (1991) 870-873
322. Gignoux B.M., Dehni N., Parc R., and Tiret E. Ileal pouch anal-anastomosis without protective ileostomy. Gastroenterol Clin Biol 26 (2002) 671-674
323. Tekkis P.P., Fazio V.W., Lavery I.C., et al. Evaluation of the learning curve in ileal pouch-anal anastomosis surgery. Ann Surg 241 (2005) 262-268
324. Tulchinsky H., Hawley P.R., and Nicholls J. Long-term failure after restorative proctocolectomy for ulcerative colitis. Ann Surg 238 (2003) 229-234
325. Karoui M., Cohen R., and Nicholls J. Results of surgical removal of the pouch after failed restorative proctocolectomy. Dis Colon Rectum 47 (2004) 869-875
326. Borjesson L., Oresland T., and Hulten L. The failed pelvic pouch: conversion to a continent ileostomy. Tech Coloproctol 8 (2004) 102-105
327. Baixauli J., Delaney C.P., Wu J.S., et al. Functional outcome and quality of life after repeat ileal pouch-anal anastomosis for complications of ileoanal surgery. Dis Colon Rectum 47 (2004) 2-11
328. Ogunbiyi O.A., Korsgen S., and Keighley M.R. Pouch salvage. Long-term outcome. Dis Colon Rectum 40 (1997) 548-552
329. Hulten L., Willen R., Nilsson O., Safarani N., and Haboubi N. Mucosal assessment for dysplasia and cancer in the ileal pouch mucosa in patients operated on for ulcerative colitis - a 30-year follow-up study. Dis Colon Rectum 45 (2002) 448-452
330. Olsen K.O., Joelsson M., Laurberg S., and Oresland T. Fertility after ileal pouch-anal anastomosis in women with ulcerative colitis. Br J Surg 86 (1999) 493-495
331. Ording Olsen K., Juul S., Berndtsson I., Oresland T., and Laurberg S. Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample. Gastroenterology 122 (2002) 15-19
332. Gorgun E., Remzi F.H., Goldberg J.M., et al. Fertility is reduced after restorative proctocolectomy with ileal pouch anal anastomosis: a study of 300 patients. Surgery 136 (2004) 795-803
333. Johnson P., Richard C., Ravid A., et al. Female infertility after ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum 47 (2004) 1119-1126
334. Oresland T., Palmblad S., Ellstrom M., et al. Gynaecological and sexual function related to anatomical changes in the female pelvis after restorative proctocolectomy. Int J Colorectal Dis 9 (1994) 77-81
335. Mortier P.E., Gambiez L., Karoui M., et al. Colectomy with ileorectal anastomosis preserves female fertility in ulcerative colitis. Gastroenterol Clin Biol 30 (2006) 594-597
336. Olsen K.O., Juul S., Bulow S., et al. Female fecundity before and after operation for familial adenomatous polyposis. Br J Surg 90 (2003) 227-231
337. Zetterstrom J., Lopez A., Holmstrom B., et al. Obstetric sphincter tears and anal incontinence: an observational follow-up study. Acta Obstet Gynecol Scand 82 (2003) 921-928
338. Walsh C.J., Mooney E.F., Upton G.J., and Motson R.W. Incidence of third-degree perineal tears in labour and outcome after primary repair. Br J Surg 83 (1996) 218-221
339. Snooks S.J., Swash M., Mathers S.E., and Henry M.M. Effect of vaginal delivery on the pelvic floor: a 5-year follow-up. Br J Surg 77 (1990) 1358-1360
340. Snooks S.J., Setchell M., Swash M., and Henry M.M. Injury to innervation of pelvic floor sphincter musculature in childbirth. Lancet 2 (1984) 546-550
341. Hahnloser D., Pemberton J.H., Wolff B.G., et al. Pregnancy and delivery before and after ileal pouch-anal anastomosis for inflammatory bowel disease: immediate and long-term consequences and outcomes. Dis Colon Rectum 47 (2004) 1127-1135
342. Remzi F.H., Gorgun E., Bast J., et al. Vaginal delivery after ileal pouch-anal anastomosis: a word of caution. Dis Colon Rectum 48 (2005) 1691-1699
343. Polle S.W., Vlug M.S., Slors J.F., et al. Effect of vaginal delivery on long-term pouch function. Br J Surg 93 (2006) 1394-1401
344. Chapman J.R., Larson D.W., Wolff B.G., et al. Ileal pouch-anal anastomosis: does age at the time of surgery affect outcome?. Arch Surg 140 (2005) 534-540
345. Church J.M. Functional outcome and quality of life in an elderly patient with an ileal pouch-anal anastomosis: a 10-year follow up. Aust N Z J Surg 70 (2000) 906-907
346. Delaney C.P., Dadvand B., Remzi F.H., Church J.M., and Fazio V.W. Functional outcome, quality of life, and complications after ileal pouch-anal anastomosis in selected septuagenarians. Dis Colon Rectum 45 (2002) 890-894
347. Little V.R., Barbour S., Schrock T.R., and Welton M.L. The continent ileostomy: long-term durability and patient satisfaction. J Gastrointest Surg 3 (1999) 625-632
348. Nessar G., Fazio V.W., Tekkis P., et al. Long-term outcome and quality of life after continent ileostomy. Dis Colon Rectum 49 (2006) 336-344
349. Castillo E., Thomassie L.M., Whitlow C.B., et al. Continent ileostomy: current experience. Dis Colon Rectum 48 (2005) 1263-1268
350. Ecker K.W., Haberer M., and Feifel G. Conversion of the failing ileoanal pouch to reservoir-ileostomy rather than to ileostomy alone. Dis Colon Rectum 39 (1996) 977-980
351. Leijonmarck C.E., Lofberg R., Ost A., and Hellers G. Long-term results of ileorectal anastomosis in ulcerative colitis in Stockholm County. Dis Colon Rectum 33 (1990) 195-200
352. Elton C., Makin G., Hitos K., and Cohen C.R. Mortality, morbidity and functional outcome after ileorectal anastomosis. Br J Surg 90 (2003) 59-65
353. May R.E. Sexual dysfunction following rectal excision for ulcerative colitis. Br J Surg 53 (1966) 29-30
354. Johnson W.R., McDermott F.T., Hughes E.S., et al. The risk of rectal carcinoma following colectomy in ulcerative colitis. Dis Colon Rectum 26 (1983) 44-46
355. Maartense S., Dunker M.S., Slors J.F., et al. Hand-assisted laparoscopic vs open restorative proctocolectomy with ileal pouch anal anastomosis: a randomized trial. Ann Surg 240 (2004) 984-992
356. Tilney H.S., Lovegrove R.E., Heriot A.G., et al. Comparison of short-term outcomes of laparoscopic vs open approaches to ileal pouch surgery. Int J Colorectal Dis 22 (2007) 531-542
357. Pishori T., Dinnewitzer A., Zmora O., et al. Outcome of patients with indeterminate colitis undergoing a double-stapled ileal pouch-anal anastomosis. Dis Colon Rectum 47 (2004) 717-721
358. Delaney C.P., Remzi F.H., Gramlich T., Dadvand B., and Fazio V.W. Equivalent function, quality of life and pouch survival rates after ileal pouch-anal anastomosis for indeterminate and ulcerative colitis. Ann Surg 236 (2002) 43-48
359. Regimbeau J.M., Panis Y., Pocard M., et al. Long-term results of ileal pouch-anal anastomosis for colorectal Crohn's disease. Dis Colon Rectum 44 (2001) 769-778
360. Lake J.P., Firoozmand E., Kang J.C., et al. Effect of high-dose steroids on anastomotic complications after proctocolectomy with ileal pouch-anal anastomosis. J Gastrointest Surg 8 (2004) 547-551
361. Aberra F.N., Lewis J.D., Hass D., et al. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology 125 (2003) 320-327
362. Heuschen U.A., Allemeyer E.H., Hinz U., et al. Outcome after septic complications in J pouch procedures. Br J Surg 89 (2002) 194-200
363. Mahadevan U., Loftus Jr. E.V., Tremaine W.J., et al. Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications. Inflamm Bowel Dis 8 (2002) 311-316
364. Subramanian V., Pollok R.C., Kang J.Y., and Kumar D. Systematic review of postoperative complications in patients with inflammatory bowel disease treated with immunomodulators. Br J Surg 93 (2006) 793-799
365. Marchal L., D'Haens G., Van Assche G., et al. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. Aliment Pharmacol Ther 19 (2004) 749-754
366. Maser E.A., Deconda D., Lichtiger S., Present D.H., and Kornbluth A. Cyclosporine and infliximab as acute salvage therapies for each other, in severe steroid-refractory ulcerative colitis. Gastroenterology 132 Suppl 2 (2007) S1132 (abstract)
367. Selvasekar C.R., Cima R.R., Larson D.W., et al. Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg 204 (2007) 956-962
368. Langholz E., Munkholm P., Davidsen M., and Binder V. Colorectal cancer risk and mortality in patients with ulcerative colitis: an epidemiologic study. Gastroenterology 103 (1992) 1444-1451
369. Leijonmarck C.E., Persson P.G., and Hellers G. Factors affecting coectomy rate in ulcerative colitis: an epidemiologic study. Gut 31 (1990) 329-333
370. Farmer R.G., Easley K.A., and Rankin G.B. Clinical patterns, natural history and progression of ulcerative colitis. A long term follow up of 1116 patients. Dig Dis Sci 38 (1993) 1137-1146
371. Vind I., Riis L., Jess T., et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol 101 (2006) 1274-1282
372. Hoie O., Wolters F.L., Riis L., et al. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology 132 (2007) 507-515